Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
Canopy Growth (Nasdaq: CGC) has completed an early prepayment of US$25 million on its senior secured term loan, following a previous US$25 million payment made on July 31, 2025. This fulfills the company's total prepayment obligations of US$50 million under the agreement with lenders announced on July 29, 2025.
The accelerated debt reduction is expected to result in US$6.5 million in annual cash interest savings, with US$4.0 million of cash interest savings specifically for fiscal 2026. The early completion of these prepayments demonstrates the company's commitment to strengthening its financial position through debt reduction and interest expense management.
STORZ & BICKEL, a subsidiary of Canopy Growth Corporation (NASDAQ: CGC), has launched the VEAZY, their most compact and accessible vaporizer to date. Priced at $249 USD, this new device marks the company's first entry into colorful design options, available in Charming Pink, Inspiring Orange, Dynamic Blue, and Alluring Black.
The VEAZY features advanced technology including a patented mini heater with conduction and convection capabilities, Bluetooth connectivity for personalized settings via a web app, and USB-C fast charging. At just 0.3lbs, the device offers three pre-set temperatures and heats up in approximately 40 seconds. The product will be distributed through online and select retail channels across more than 100 countries worldwide.
Canopy Growth (Nasdaq: CGC) has established a new US$200 million at-the-market (ATM) equity program to strengthen its financial position. The program allows the company to issue and sell common shares through concurrent public offerings in the United States and Canada, with Canadian sales limited to US$50 million.
The ATM program will be effective until June 5, 2027, or until the total offering amount is reached. Shares will be sold at prevailing market prices through BMO Nesbitt Burns Inc. (Canada) and BMO Capital Markets Corp. (USA). The proceeds will be used for business investments, potential acquisitions, working capital, and possible debt repayment.
Canopy USA (NASDAQ:CGC) has appointed Eric Ruhle as Vice President of Brand Sales to oversee sales strategy across its cannabis brand portfolio. Ruhle brings over 11 years of cannabis industry experience, most recently serving as Senior Regional Sales Manager at Kiva Sales & Services.
In his new role, Ruhle will focus on expanding retail presence, strengthening distributor partnerships, and launching go-to-market initiatives to drive revenue growth. His previous leadership positions at Marley Natural, dosist, and Final Bell demonstrate his expertise in scaling multi-brand portfolios and developing retail partnerships.
Canopy USA (NASDAQ:CGC) has announced the appointment of a new executive leadership team to drive its expansion across the U.S. cannabis market. The key appointments include Casey Rash as Chief Financial Officer, Rebecca Kirk as Chief Operating Officer, and Kelly Flores as Chief Business Development Officer.
Under the leadership of President Brooks Jorgensen, the team will focus on portfolio growth, operational improvements, and market expansion. The company's platform combines assets from Acreage, Jetty, and Wana, aiming to deliver consistent quality products and trusted brands nationwide.
Canopy Growth (NASDAQ:CGC) has announced the mailing of proxy materials for its upcoming 2025 Annual General and Special Meeting, scheduled for September 26, 2025, at 1:00 PM ET. The virtual meeting requires a quorum of 33 1/3% of outstanding shares to proceed.
Shareholders will vote on four key items: director elections, auditor reappointment, a proposed reverse stock split, and an advisory vote on executive compensation. The board recommends voting FOR all resolutions. Shareholders of record as of August 1, 2025, can vote online at proxyvote.com, by phone, or through various other platforms depending on their broker.
Canopy Growth (Nasdaq: CGC) reported strong Q1 FY2026 financial results, with total revenue increasing 9% year-over-year to $72.1 million. The company's Canada adult-use cannabis revenue surged 43% to $27 million, driven by increased distribution and strong demand for new products, particularly Claybourne infused pre-roll joints.
The company achieved $17 million of its planned $20 million annualized savings target since March 2025, with SG&A expenses down 21% year-over-year. However, gross margin decreased to 25% from 35% in Q1 FY2025, primarily due to lower Storz & Bickel sales and product mix shifts. The company reported a net loss of $41.5 million, showing a 68% improvement from the previous year.
Additionally, Canopy Growth announced the appointment of Shan Atkins to its Board of Directors, bringing extensive retail strategy and operations experience.
Canopy Growth (Nasdaq: CGC) has expanded its medical cannabis portfolio in Australia with the launch of its 7ACRES brand. The company introduced two high-THC sativa strains: Ultra Jack and Jack Frost, available in 10g flower formats.
The expansion complements Canopy's existing Australian presence, which includes Tweed flower products and Spectrum Therapeutics oils. This launch leverages the company's improved global supply chain and Canadian production capabilities to strengthen its international medical platform.
Canopy Growth (Nasdaq: CGC) has appointed Miles Worne as Managing Director of European Markets, effective August 11, 2025. Worne, who previously served as President of Curaleaf International, brings over 20 years of experience in cannabis, healthcare, and consumer sectors.
The appointment aligns with Canopy Growth's strategic focus on European expansion, particularly in established medical markets. The company's European operations are supported by EU-GMP certified supply from its Kincardine facility, processing capabilities at St. Leon-Rot in Germany, and a global supply chain infrastructure.
Canopy Growth (NASDAQ:CGC) has announced a significant debt reduction initiative through an agreement with its lenders. The company will make three prepayments totaling US$50 million to reduce its Senior Secured Term Loan by March 31, 2026.
The prepayments will be made in three installments: US$25 million by July 31, 2025, US$10 million by December 31, 2025, and US$15 million by March 31, 2026. This debt reduction is expected to lower the company's annual cash interest expense by US$6.5 million.
Additionally, Canopy USA received consent to secure US$22 million in additional funding for Acreage Holdings and its subsidiaries.